

Florian Stumpf, MD¹; Ann K. Jay, MD²; Daniel R. Wang, MD¹; Rashmi S. Thakkar, MD¹
¹Medstar Georgetown University Hospital, ²Transparent Imaging


Purpose

Meningiomas are the most common primary central nervous system (CNS) neoplasm, making up more than a third of CNS tumors. While the majority of meningiomas exhibit classic imaging features in characteristic locations such as along the convexity and skull base, they can occasionally present with atypical features. Additionally, extra-axial masses can present with imaging features that mimic meningiomas; both scenarios can cause diagnostic dilemmas.

While there are no definite imaging criteria differentiating typical (WHO grade 1) meningiomas from atypical (grade 2) and anaplastic (grade 3) meningiomas, certain features may help predict higher tumor grades which may aid in pre-operative planning and management.

Recognizing certain imaging features that may alert clinicians of potentially lesions, this poster aims to provide an overview of typical and atypical imaging features of meningiomas, highlights features that can predict higher grade lesions, address common pitfalls in imaging interpretation, and offer a differential diagnosis of important alternative considerations.


Characteristic Imaging Features




Cytogenomics and Locations

HISTOLOGIC SUBTYPES	MOLECULAR MARKERS	Hyperostosis:
Grade 1: <ul style="list-style-type: none">MeningoepithelialFibroblasticTransitionalSecretoryPseudopapillaryAngiomatousMicrocysticLymphoplasmacyte-richMetaplastic	Less aggressive: <ul style="list-style-type: none">KLF4TRAF7: HyperostosisKLF4 + TRAF7 = Secretory typeAKT1: Meningoepithelial typePOLR2: Sellar/parasellar; only in grade 1 More aggressive: <ul style="list-style-type: none">NF2: Common in sporadic and syndromic/familial and all gradesCDKN2A/BBAP1PBRM1	<ul style="list-style-type: none">TRAF7Lymphoplasmacyte-rich* En plaque meningiomas
Grade 2: <ul style="list-style-type: none">Clear cellChoroidAtypical	Grade 3: <ul style="list-style-type: none">AnaplasticRhabdoidPapillary	Peritumoral edema: <ul style="list-style-type: none">SecretoryAngiomatousMicrocysticLymphoplasmacyte-rich

NON-SKULL BASE • More likely to be WHO grade 2/3




SKULL BASE • More likely to be WHO grade I, have hyperostosis



Meningioma Grading

Meningiomas are divided into WHO grade 1 (benign), grade 2 (atypical), and grade 3 (anaplastic) based on histopathology criteria with the addition of molecular profiles in the 2021 WHO update. Grades 2/3 meningiomas exhibit increased parenchymal invasion and have an increased rate of recurrence with decreased five-year survival rates.



Imaging Features Predictive of Higher Grade


While there are no imaging features to accurately distinguish between grade 1 and grade 2/3 meningiomas, the following features can help predict higher grade tumors and which tumors may have increased risk of recurrence. Ultimately however, grade and recurrence risk will be based on histologic features and molecular markers.

HIGHER GRADE

- Larger tumor volumes
- Ill-defined/blurry tumor-brain interface
- Low ADC (<0.72)
- Irregular or non-spherical shape
- Heterogeneity
- Necrosis
- Non-skull base location


RECURRENCE RISK

- Larger tumor volume
- Significant peritumoral edema



Potential Pitfalls


Peritumoral Edema



Large Tumor Volumes

Very large right sphenoid wing meningioma with extension into the cavernous sinus, sphenoid sinuses, pituitary sella, and foramen ovale. Marked heterogeneity with central necrosis and hemorrhage. Pathology showed ≤ 1 mitotic figure per HPF; no hypercellularity or necrosis; no brain invasion.


Large volume masses can have more aggressive features despite their benign nature



Combination of Findings

Large, homogeneous meningioma in the bifrontal parafalcine region with distinct CSF cleft, prominent PTE, typical spoke-wheel pattern of enhancement. The left margins of the mass are well-defined; however, the right margins are indistinct. Pathology showed prominent macronucleoli, 4 mitoses per 10 HPFs, rare foci of necrosis. No hypercellularity, small cell change or loss of architectural pattern. Ki-67 of 15%.


Important to evaluate all areas of the meningiomas as only certain areas may exhibit more aggressive features.



Bony erosion and Cognitive Biases

43-year-old woman with metastatic breast cancer presents for tumor staging. Thick, nodular dural enhancement along the falx bilaterally with invasion into and occlusion of the superior sagittal sinus. Associated calvarial sclerosis plus bony erosion seen on CT. Constellation of findings were concerning for dural metastases. Pathology showed a grade 1 meningioma without mitotic figures, hypercellularity, macronucleoli, small cell change, or architectural distortion.

En plaque meningiomas are usually osteoblastic but may have areas of osteolysis which can appear aggressive. Additionally, anchoring bias (relying too heavily on clinical hx) can cause interpretation errors




Differential Diagnoses

Benign Extra-Axial Masses


Solitary fibrous tumors are rare, dural based masses of mesenchymal origin. They have similar imaging findings as meningiomas: well-defined, solidly enhancing, dural-based masses. They may even have dural tails. SFTs, however, more commonly have **flow voids**, **lobulated margins** and usually cause bony erosion rather than hyperostosis.

However, hypervascular **meningiomas** can have a similar appearance with **flow voids** and **increased surrounding vascularity**.



Typical right **parafalcine meningioma** without superior sagittal sinus invasion.


Inferior to this is another homogeneously enhancing extra-axial lesion. However, unlike typical meningiomas, there is **more solid enhancement**, **marked T2 hypointensity**, and **pulsation artifact** on post contrast FLAIR. A CTA was recommended, which confirmed a left **A2 aneurysm**.




Malignant Extra-Axial Masses

This metastatic neuroendocrine tumor (NET) has characteristic imaging features of a meningioma. Meningioma should be the leading and possibly the only, pre-operative dx provided. As meningiomas have many mimickers, it is important to scrutinize assoc findings which may warrant a dx; however, in this case, there were none.

This esophageal CA met has dural tails and even rim E+ on FLAIR post contrast, which is highly specific for meningiomas! The irregular shape, areas of T2 hypo, and clinical hx were helpful to suggest a more aggressive dx.




Malignant Extra-Axial Masses



Rarely, meningiomas can have extracranial extension, which present as a slow growing "bump" on the head. The associated bony changes can be either osteoblastic (more common), osteolytic, or a combination, as seen in this example. Rare lesions that can have a similar appearance with both dural and extracranial involvement are aggressive hemangiomas (much more common in the spine) and primary dural lymphomas. Primary dural lymphomas are uncommon and are usually a low-grade, B-cell marginal lymphoma.

The Use of DOTATATE PET

Homogeneously enhancing right cavernous sinus meningioma with extension along the preoptine dura and right tentorium



Meningiomas are known to express somatostatin receptor 2 (SSTR2). PET-CT using the radiotracer ⁶⁸Ga-DOTATATE, which is an SSTR2 analog, has a higher sensitivity and specificity for detecting meningiomas than MRI or ¹⁸FDG PET-CT.

⁶⁸Ga-DOTATATE PET-CT is instrumental in:

- Differentiating meningiomas from other dural-based masses
- Caveat: Cancers that also express SSTR2 (Breast, neuroendocrine tumors, etc)
- Differentiating post-surgical changes from residual tumor; particularly in guiding radiation therapy in grade 2 meningiomas
- Detect recurrence

Contact

Rashmi S. Thakkar, MD
Medstar Georgetown University Hospital
3800 Reservoir Road NW, Washington, DC 20007
Rashmi.S.Thakkar@medstar.net
202-444-3358

References

- Ostrom QT, Patil N, Cioffi G, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Neuro Oncol. 2020;22(Supplement_1):iv1–iv96.
- Meyer HJ, Wienke A, Surov A. ADC values of benign and high grade meningiomas and associations with tumor cellularity and proliferation - A systematic review and meta-analysis. J Neurol Sci. 2020 Aug 15;415:116975. doi: 10.1016/j.jns.2020.116975. Epub 2020 Jun 5. PMID: 32535250.
- Han T, Zhang J, Liu X, Zhang B, Deng L, Lin X, Jing M, Zhou J. Differentiating atypical meningioma from anaplastic meningioma using diffusion weighted imaging. Clin Imaging. 2022 Feb;82:237–243. doi: 10.1016/j.clinimag.2021.12.004. Epub 2021 Dec 11. PMID: 34915318.
- Battal B, Zamora C. Imaging of Skull Base Tumors. Tomography. 2023 Jun 21;9(4):1196–1235. doi: 10.3390/tomography9040097. PMID: 37489465; PMCID: PMC10366931.
- Soni N, Ora M, Bathia G, Szekeres D, Desai A, Pillai JJ, Agarwal A. Meningioma: Molecular Updates from the 2021 World Health Organization Classification of CNS Tumors and Imaging Correlates. AJNR Am J Neuroradiol. 2024 Oct 31. doi: 10.3174/ajnr.A8368. Epub ahead of print. PMID: 38844366.
- Rachinger W, Stoecklein VM, Terpolilli NA, Haug AR, Ertl L, Pöschl J, Schüller U, Schichor C, Thon N, Tonn JC. Increased ⁶⁸Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue. J Nucl Med. 2015 Mar;56(3):347–53. doi: 10.2967/jnumed.114.149120. Epub 2015 Jan 29. PMID: 25635133.